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Abstract
BACKGROUND—To test the hypothesis that infants born to obese women with pregestational 
type 2 diabetes mellitus (IBDM) have ventricular dysfunction at one month that is associated with 
markers of maternal lipid and glucose metabolism.
METHODS—In a prospective observational study of IBDM (OB+DM, n=25), echocardiography 
measures of septal, left (LV) and right ventricular (RV) function and structure were compared at 
one month of age to infants born to OB mothers without DM (OB, n=24), and non-OB without 
DM (Lean, n=23). Basal maternal lipid and glucose kinetics and maternal plasma and infant (cord) 
plasma were collected for hormone and cytokine analyses.
RESULTS—RV, LV, and septal strain measures were lower in the OB+DM infants vs. other 
groups, without evidence of septal hypertrophy. Maternal hepatic insulin sensitivity, maternal 
plasma free fatty acid concentration, and cord plasma insulin and leptin most strongly predicted 
decreased septal strain in the OB+DM infants.
CONCLUSION—IBDM’s have reduced septal function at one month in the absence of septal 
hypertrophy, which is associated with altered maternal and infant lipid and glucose metabolism. 
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These findings suggest that maternal obesity and DM may have a prolonged impact on the 
cardiovascular health of their offspring, despite resolution of cardiac hypertrophy.
Since the mid-1940’s, cardiac hypertrophy at birth, particularly in the septum, has been a 
well-known phenomenon in infants born to women with pre-gestational type 2 diabetes 
mellitus (IBDM)(1). This hypertrophy is thought to be transient, often resolving in two 
weeks to six months of age.(1–4) Emerging evidence suggests that ventricular function 
during gestation and at birth is impaired in IBDM, even in the absence of cardiac 
hypertrophy.(5, 6) Although unclear from the current literature, early life ventricular 
abnormalities may predispose these children to develop overt cardiac dysfunction as adults 
or as other cardiovascular risk factors emerge.
Mechanisms for ventricular contractile abnormalities in IBDM remain obscure. Some 
data(5, 7, 8), but not all(9), suggest that maternal and infant glycemia is associated with 
impaired cardiac function. Recent evidence points to a possible relationship between 
maternal adipose tissue/lipid metabolism and adverse cardiac function in the offspring.(6, 
10) Additional findings demonstrate the association of maternal lipid metabolism with 
elevated infant birth weight in diabetic pregnancy.(11–13) None of these previous studies 
have separated the effects of maternal obesity and diabetes mellitus on cardiac function in 
the infants, nor have they examined the predictive value of maternal lipid and glucose 
metabolism on infant ventricular function. Furthermore, advances in neonatal cardiac 
imaging permit a more comprehensive assessment of ventricular function in neonates that 
could not be previously obtained with conventional imaging.(14)
Therefore, the primary objective of this study was to compare left (LV) and right ventricular 
(RV) function in infants born to three groups: 1) obese women with pre-gestational type 2 
diabetes mellitus (OB+DM), 2) obese women without diabetes mellitus (OB), and 3) non-
obese women without diabetes mellitus (Lean) with conventional and two-dimensional 
quantitative echocardiography. The secondary objective was to examine indices of maternal 
lipid metabolism as predictors of infant ventricular function in this cohort. Our hypothesis 
was that ventricular functional abnormalities will be greatest in infants born to obese women 
with DM and would be associated with markers of maternal lipid metabolism.
METHODS
This was a prospective observational study of three groups of women who were receiving 
prenatal care at the Women’s Health Center at Barnes-Jewish Hospital/Washington 
University School of Medicine in St. Louis between May 2011 and December 2013, and 
their neonates. Infants were stratified into three separate groups based on maternal body 
mass index and diabetic status: Infants born to 1) obese women with pre-gestational, type 2 
DM, requiring insulin (White Class B or C [OB+DM]), 2) obese women without DM or 
insulin resistance (no pre-gestational or gestational and normal 50g glucose challenge, 
[OB]), and 3) non-obese controls without DM (Lean). Obesity was defined as pre-pregnancy 
body mass index between 30 and 45 kg/m2. Women with pre-gestational DM were on 
insulin therapy, and had HbA1C ≤ 8 (183 mg/dL, 64 mmol/mol) for greater than 3 months 
prior to pregnancy as previously described(13). Exclusion criteria for all women included: 1) 
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multiple gestation pregnancy, 2) inability to provide voluntary informed consent, 3) current 
self-reported use of illegal drugs (cocaine, methamphetamine, opiates), 4) current smoker 
who did not consent to cessation, 5) current usage of daily medications by class: 
corticosteroids, beta-blockers (known to affect lipid metabolism) or anti-psychotics (known 
to alter insulin resistance and metabolic profiles), and 6) known fetal anomalies. For women 
without DM, exclusion criteria included: 1) diagnosis or history of gestational diabetes or 
abnormal 50g glucose challenge between 24 and 28 weeks, 2) pre-pregnancy DM or 3) prior 
macrosomic (>4000g) infant. This study was approved by the Human Research Protection 
Office at Washington University School of Medicine (IRB#201012828, NCT#01346527).
Assessment of Cardiac Structure and Function
A transthoracic complete M-mode, two-dimensional (2D) and Doppler echocardiographic 
examination was performed at one month of age with a commercially available ultrasound 
imaging system (Vivid 7 and 9; General Electric Medical Systems, Milwaukee, Wisconsin). 
The timing of the echocardiographic study was carefully selected to occur at one month of 
age to avoid the early postnatal period of cardiopulmonary instability with a patent ductus 
arteriosus (PDA) and rapidly decreasing pulmonary vascular resistance. All of the infants 
were clinically healthy at birth and were discharged home with their mothers. None of the 
infants in this study had evidence of a PDA or altered pulmonary hemodynamics at one 
month of age. All the infants were stable in room air at the time of the study. All exams were 
performed two hours after feedings. One designated pediatric cardiac sonographer, blinded 
to the maternal and infant clinical and demographic data, and experienced in acquiring 
images for conventional and 2D speckle tracking echocardiographic (2DSTE) analysis 
obtained all the echocardiographic images using a transducer (7.5–12 MHz) center-
frequency phased array probe and optimized to visualize the myocardial walls.(15) The 
echocardiographic images were acquired according to the guideline of the American Society 
of Echocardiography(16) and with a previous validated protocol in decubitus position during 
restful period without changing the position of the infant or disturbing the hemodynamic 
condition to minimize heart rate and respiratory variation during the image acquisition.(15, 
17)
Cardiac Structure—Relative wall thickness (RWT) and LV mass index (LVMI, Devereux 
formula) were calculated using M-mode imaging of the LV in the parasternal short-axis 
view, and LVMI was indexed to height2.7 (g/m2.7).(16, 18) Using M-mode imaging, 
interventricular septal wall thickness was measured in the parasternal long axis view at the 
level of the tip of the mitral valve midway between the apex and the crux of the heart. The 
RV linear dimensions (inflow at base and mid-cavity, length, and tricuspid valve annulus) 
were measured from the apical four-chamber view. The RV linear dimensions at the 
proximal and distal outflow were measured from the parasternal short axis view.
Cardiac Function—Conventional indices of LV function, shortening fraction (SF) and 
biplane LV ejection fraction (EF), were measured according to the guidelines of the 
American Society of Echocardiography.(16, 19, 20) Myocardial mechanics were analyzed 
by the quantification of LV, RV, and septal longitudinal strain (%) and strain rate (%/sec) by 
2DSTE, an emerging quantitative echocardiographic technique to characterize ventricular 
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function in neonates.(14) The strain parameters were acquired using a previously validated 
image acquisition and data analysis protocols from our laboratory.(15, 17) A frame rate to 
heart rate ratio (FR/HR) between 0.7 and 0.9 frames/sec per bpm was utilized to optimize 
myocardial speckle tracking and mechanical event timing.(21) LV global longitudinal strain 
(LV GLS, %) and systolic, early and late diastolic global longitudinal strain rates (LV 
GLSRs, GLSRe, and GLSRa, (%/sec) respectively) were calculated by averaging all values 
of the regional peak longitudinal strain obtained from 17 segments in two-chamber, apical 
long-axis, and apical four-chamber views.(22) Peak strain was measured as end-systolic 
strain at the closure of the aortic valve.(23) RV global longitudinal strain (RV GLS,%) was 
measured from an RV focused apical four-chamber view and calculated by averaging all 
values of the regional peak longitudinal strain obtained from six segments. LV and RV 
segmental longitudinal strain (SLS, %) were measured at the apical-, mid-, and basal- 
ventricular levels in the RV and LV free walls. Septal GLS and GLSRs, GLSRe and GLSRa 
measures were calculated by averaging all values of the SLS obtained from 9-segments in 
the two-chamber, apical long-axis, and apical four-chamber views along the septal wall. A 
lower magnitude of strain (%) and strain rate (%/sec) indicates worse ventricular function. A 
single observer (PL), who was blinded to the maternal and infant clinical and metabolic 
values, analyzed the strain imaging using vendor customized commercially available 
software (EchoPAC; General Electric Medical Systems, Waukesha, WI, version 110.0.x). 
We have previously demonstrated reliable intra- and inter- observer reproducibility of strain 
imaging in neonates.(15, 17, 24)
Lipid and Glucose Metabolism Studies
All pregnant women underwent basal lipid and glucose kinetic studies (using stable isotope 
tracer methodology) and a subset (n=49) also underwent hyperinsulinemic-euglycemic 
clamp during gestation weeks 32–36 as previously described.(13) Maternal plasma at 32–36 
weeks gestation and infant (cord) plasma at birth was collected for hormone and cytokine 
analyses as previously described.(13)
Statistical Analyses
Normally distributed demographics, plasma metabolite, hormone variables, and 
echocardiographic variables between groups were examined by one-way analysis of variance 
(ANOVA) and group differences were compared through post-hoc testing using Tukey 
honestly significant difference testing. Non-normally distributed variables determined by the 
Shapiro-Wilk test were examined by chi-square and independent samples Kruskal-Wallis 
one-way ANOVA. Relationships between outcome variables were examined using univariate 
(Pearson Product Correlation Coefficient) and standardized linear regression analysis with 
Bonferroni adjustment for multiple correlations were used to refine the ability to predict LV, 
RV, and Septal global and regional deformation strain combining multiple metabolic 
measures. Univariate analysis was utilized to determine the best predictors to enter in the 
model (significant correlation > 0.4) and then backward step-wise regression was performed. 
Statistical significance was considered at p < 0.05. Due to the lack of data regarding the 
relationship between maternal and infant lipid and glucose metabolism with postnatal 
ventricular function, and the exploratory nature of this study, we used data from our previous 
work in nongravid insulin- resistant and control participants and data from our deformation 
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studies to estimate sample size, assuming an alpha of 0.05, where 20 subjects per group 
would provide 99% power to detect 20% differences in echocardiographic measures 
between groups (13, 24, 25). All statistical analyses were performed using SPSS (IBM, 
Armonk, NY).
RESULTS
Seventy-nine women were enrolled and studied at 32–36 weeks’ gestation. Of the 79 
mothers enrolled in the original study,(13) 72 of the neonates returned at one month of age 
(30 ± 5 days) and received conventional and speckle-tracking echocardiograms between 
May 2011 and December 2013. Infants were stratified into the three separate groups: 1) OB
+DM, n=25, 2) OB, n=24, and 3) Lean, n=23. The infants included were from a previous 
study reported by our group, but their echocardiographic data was not initially analyzed in 
the study.(13) There was a statistical difference between the gestational age at birth between 
the OB+DM (37 ± 2 weeks) and the OB (39 ± 2 weeks) and Lean (39 ± 1 weeks) groups, 
but after adjusting for birthweight, gender, and postnatal age at the time of echocardiogram 
univariate correlations did not reveal relationships between the echocardiographic indices 
and gestational age between the groups. Table 1 displays the demographic, clinical, and 
metabolic characteristics of the study population.
Assessment of Cardiac Structure and Function
Ventricular Structure—LV mass, LV mass index, relative wall thickness, and 
interventricular septal wall thickness, were not different between the three groups. RV major 
dimension was only significantly higher between the OB+DM and the OB groups (p < 0.05), 
(Table 2).
Ventricular Systolic Function—The results of the ventricular functional analyses are 
provided in Table 2. There were no differences in conventional measures of LV systolic 
function (EF and SF) among groups. Septal GLS was significantly lower in OB+DM 
compared to both the OB and Lean (p < 0.005 for both). Septal SLS displayed a preserved 
normal apex to base gradient pattern in all three groups (p < 0.05), but SLS at the apex and 
mid-level of the septum were significantly lower in OB+DM compared to OB and Lean (p < 
0.002 for both). LV GLS was significantly lower in OB+DM vs. Lean groups (p < 0.05). LV 
SLS also displayed a preserved normal apex to base gradient pattern (p < 0.05), but LV SLS 
was significantly lower at the basal- and mid-ventricular level in OB+DM vs. Lean (p < 
0.05). RV GLS was significantly lower in OB+DM vs. Lean (p < 0.05). RV SLS displayed a 
preserved normal base to apex gradient pattern (p < 0.05) with no differences in values in all 
three groups. RV and LV systolic strain rate (SRs) patterns were all similar amongst the 
groups.
Ventricular Diastolic Function—The feasibility of GLSRe and GLSRa was 93%, as 
seven out of 72 patients had fused early and late strain curves and were excluded from the 
analysis. LV GLSRe and GLSRa were not different between the groups, however both RV 
and Septal GLSRe were significantly lower in OB+DM vs., Lean (p < 0.001).
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Relationships between Maternal Lipid and Glucose Kinetics with Ventricular Deformational 
Indices
Using univariate analysis in OB and OB+DM women only (n=49), several maternal and 
infant variables were tested for association with LV, RV, and septal GLS. Variables found to 
have an association with septal GLS (R ≥ 0.40, P<0.05) included maternal age, endogenous 
glucose production per unit of insulin during the baseline period and during 
hyperinsulinemia, glucose rate of disappearance during hyperinsulinemia (i.e. insulin 
sensitivity), suppression of endogenous glucose production with hyperinsulinemia, and 
plasma free fatty acid concentration during hyperinsulinemia. Infant variables with a 
correlation with septal SLS (R ≥0.40, p<0.05) included cord plasma insulin, C-peptide and 
leptin and infant birth weight. Using these variables in a backward step-wise regression 
analysis (multicollinearity: tolerance=0.52–0.78, variance inflation factor=1.3–1.9), a model 
including maternal plasma free fatty acid concentration during hyperinsulinemia, 
suppression of endogenous glucose production with hyperinsulinemia, infant birth weight 
and cord plasma insulin and leptin most strongly predicted decreased septal strain in the OB
+DM (adjusted R2=0.62). None of the maternal or infant lipid and glucose metabolism 
variables were associated with LV or RV strain measures.
DISCUSSION
In this study we utilized an emerging non-invasive echocardiographic modality, deformation 
imaging by 2DSTE, to quantitatively characterize ventricular performance and assess early-
stage disease-related cardiac changes in IBDM at one month of age. The principal and novel 
finding of this study is that IBDM have reduced septal strain (septal function) in the absence 
of septal hypertrophy that was associated with alterations in maternal lipid and maternal and 
infant glucose metabolism. In addition, IBDM had decreased RV and LV deformation values 
with relatively preserved ventricular structure.
Pregestational diabetes has an effect on early embryonic development that may alter cardiac 
morphogenesis during gestation and extend to the neonatal period, exposing the IDBM to 
varying degree of myocardial damage.(5) The high levels of glucose in the maternal blood 
will cause fetal hyperglycemia through the placenta leading to fetal cardiomyocyte injury 
directly with excessive apoptosis of myocardial cell.(26) Pregestational type 2 DM is also 
characterized by hyperlipidemia.(6, 27) As the pregnancy progresses, the excessive 
availability of lipids and higher maternal free fatty acid concentration might lead to 
increased fatty acid delivery to the fetus resulting in lipid accumulation within the fetal 
cardiomyocyte.(6, 26) The fetal heart adapts to the hyperlipidemia by increasing the 
expression of fatty acid metabolizing proteins, thereby increasing the reliance on fatty acids 
as energy.(6, 26) This adapting heart is initially able to maintain cardiac output under these 
conditions. However, the continued exposure of the fetal heart to this metabolic environment 
eventually leads to apoptosis, fibrosis, and contractile dysfunction.(6) In this study we found 
that several maternal and infant metabolic variables had associations with decreased septal 
strain in infants born to obese and diabetic women, including maternal hepatic insulin 
sensitivity, maternal plasma free fatty acid concentration, and cord blood insulin and leptin.
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The complex interaction between excessive glucose and lipid metabolism affects the heart of 
IBDM in multiple ways, including cardiac malformations, hypertrophic cardiomyopathy 
(even with good maternal glycemic control), and functional impairment (even in the absence 
of structural changes).(28) The most common cardiac pathology in IBDM is asymmetrical 
septal hypertrophy.(28–30) Myocardial mass is thought to increase because of the presence 
of higher levels of fetal insulin during gestation that can lead to septal wall dysfunction 
immediately after birth. The septal wall dysfunction can occur in systole, but more 
commonly presents in diastole.(22) The majority of the IBDM’s are asymptomatic despite 
this dysfunction, and the observed septal wall hypertrophy is typically transient.(1–4) In the 
current study, septal wall thickness was not different between the three groups at one month 
of age, but global and segmental longitudinal strain at the apex and mid-level of the septum 
were significantly lower in OB+DM compared to OB and Lean groups. Diastolic strain rate 
measures were also decreased in OB+DM compared to OB and Lean groups, with preserved 
systolic strain rate measures. Wang et al. found similar significantly decreased longitudinal 
strain in the apical segments of the septum in fetuses of women with DM.(30)
Interventricular septal wall thickening and dysfunction in the IDBM may transiently disrupt 
the performance of both the LV and RV in the early neonatal period.(31) In this study, LV 
morphology was not different among groups, but at one month of age both septal and LV 
global longitudinal strain were lower in OB+DM infants in comparison with Lean infants. 
Al Biltagi et al. utilized 2DSTE derived LV deformation imaging to assess LV function in 
IBDM in the immediate postnatal period and found reduced LV longitudinal strain and 
impaired systolic function, but did not distinguish between pre-gestational type 1 and type 2 
DM. Previous studies using tissue Doppler and 2DSTE have observed similar decrease in 
LV GLS with fetuses of obese and DM mothers.(6, 30) Russel et al. demonstrated that in 
fetuses of pregestational diabetic mothers altered cardiac function (detected by decreased 
strain imaging) is evident before cardiac structural changes.(32) Combined with our results, 
these studies may suggest that altered cardiac function not only precedes cardiac structural 
changes, but persists from gestation through the early postnatal period, even after the 
morphological alterations resolve.
The impact of IBDM on LV diastolic function is unclear from the current literature. (5, 31, 
33) Weber et al. found normal LV early/late velocity ratio in the fetuses and neonates of 
well-controlled pregestational diabetic mother.(33) Kozak-Barany et al.(31) and Al-Biltagi et 
al.(5) found that LV diastolic function was significantly impaired in infants in the first week 
of age, even in the presence of well-controlled glycemia.(31) In our study LV diastolic 
function, as measured by early and late strain rate, was preserved at one month of age. 
Although, there may be a component of LV diastolic dysfunction in the early transitional 
period that reflects the abnormal myocardial relaxation and slower LV filling, the resolution 
of morphological abnormalities appears to be followed closely by the normalization of LV 
diastolic function.
Deformation imaging by 2DSTE has also been shown to have a greater sensitivity for 
measuring global and regional LV function than conventional echocardiography in neonates.
(14) In the first week of age, studies have shown a decrease in SF in infants born to mothers 
with pre-gestational and gestational DM,(5) while other studies have demonstrated normal 
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ejections fraction in gestational diabetes.(34) In this study, we found decreased LV global 
and segmental longitudinal strain with preserved ejection fraction and SF in infants born to 
OB+DM at one month of age. The clinical significance of these results lie in the notion that 
advances in neonatal cardiac imaging with 2DSTE now provide the capability to obtain 
quantitative information that often supersedes the qualitative information from conventional 
methods; and permit a more comprehensive (regional and global) assessment of LV function 
in neonates that could not be previously obtained.(14)
Pre-existing maternal diabetes alters both LV and septal performance and potentially 
complicates RV function as well.(30) There is a paucity of studies(6, 30) that have 
characterized RV function with deformation imaging by 2DSTE in the fetus of 
pregestational DM, but none in IBDM. Our study in neonates showed that RV global 
longitudinal strain and early diastolic strain rate were significantly decreased in the OB+DM 
infants, which is a similar finding to the reported altered RV deformation values in fetuses of 
gestational diabetes.(30) There are a few mechanisms that could explain RV dysfunction in 
IBDM. The pathways that are most responsible for RV remodeling in IBDM likely include 
insulin resistance, and amplified sympathetic nervous and renin-angiotensin-aldosterone 
systems.(26, 35–37) The common link between the pathways is the accumulation of 
collagen in the myocardium and development of myocardial fibrosis, which likely results 
from prolonged hyperglycemia with advanced glycation end-products and excessive 
production of oxygen free radicals.(37) These changes may lead to a loss of elasticity with 
an increase in ventricular stiffness that first causes diastolic dysfunction, then hypertrophy 
and finally systolic dysfunction.(26, 35) In our study, we observed: 1) diastolic dysfunction, 
as manifested by decreased RV global longitudinal strain rate at early diastole; 2) slightly 
altered RV morphology (increased RV major); and 3) subsequent systolic dysfunction seen 
through decreased RV global longitudinal strain in IBDM.
The strongest potential cause for the deterioration of RV function maybe the 
“interventricular interaction” achieved through the septum.(35) We demonstrated that the 
apex-to-base gradient in the RV free wall longitudinal strain was preserved between the 
three groups, but that RV GLS was significantly decrease in the OB+DM. The RV GLS 
measurement includes part of the septal wall from the apical four-chamber view, further 
supporting the significance of this interventricular dependence.(35)
This study has important limitations. There is evidence that the fetus of a mother with 
pregestational type 2 DM has decreased myocardial deformation in the longitudinal, radial, 
and circumferential direction, suggesting diffuse pattern of myocardial involvement.(6) In 
this study we only evaluated longitudinal strain imaging, as the feasibility and 
reproducibility of radial and circumferential strain has not been well described in neonate, 
and GLS remains the most reliable quantitative tool of the three to assess ventricular 
function in infants.(15) We did not assess torsional mechanics at one month of age, but 
recognize the utility of this emerging speckle tracking modality to assess ventricular 
mechanics.(5, 34)
We chose to study the neonates at one month of age, rather than at birth, to avoid the early 
postnatal period of cardiopulmonary instability. Our group has previously developed a 
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standardized cardiac strain imaging protocol to limit the variability in image acquisition.(15) 
Although scan-rescan analysis was not performed in this study, one dedicated sonographer, 
experienced in conventional and quantitative neonatal echocardiography acquired all of the 
images, further decreasing the variability in image acquisition. Our study was also limited 
by the small sample size in each group, but 20 neonates was determined to be enough to 
detect group differences in the outcome variables. Although the current literature does not 
yet support a link between altered septal function at one month of age and adult ventricular 
dysfunction, future longitudinal studies are needed to follow a larger cohort with serial 
echocardiograms from early gestation to birth, through the late neonatal period, and into 
childhood to further investigate these associations and questions.
CONCLUSION
In conclusion, infants born to obese women with pregestational type 2 DM have reduced 
interventricular septal wall function at one month of age in the absence of septal 
hypertrophy, which is associated with altered maternal and infant lipid and glucose 
metabolism. In addition, LV and RV function are decreased. These findings suggest that 
maternal obesity and DM may have a prolonged impact on the cardiovascular health of their 
offspring, despite resolution of cardiac hypertrophy. Aggressive maternal glucose and lipid 
metabolism management during pregnancy in women with diabetes to modulate infant 
cardiac dysfunction might be warranted.
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−
1.
8 
± 
0.
4 
(−
1.2
, −
2.6
)
0.
65
 
SL
S 
A
pe
x
 (%
)
−
22
.5
 ±
 1
.9
 (−
19
.1,
 −2
5.5
)
−
23
.0
 ±
 6
.3
 (−
6.3
, −
28
.6)
−
20
.6
 ±
 2
.9
 (−
11
.0,
 −2
6.2
) *
 
†
0.
00
2
 
SL
S 
M
id
 (%
)
−
18
.0
 ±
 1
.6
 (−
15
.3,
 −3
5.0
)
−
18
.5
 ±
 1
.5
 (−
15
.2,
 −2
1.0
)
−
16
.5
 ±
 2
.6
 (−
8.1
, −
22
.4)
 *  
†
0.
00
2
Se
pt
al
 d
ia
sto
lic
 fu
nc
tio
n
 
G
LS
Re
 (1
/se
c)
3.
0 
± 
0.
4 
(2.
0, 
3.7
)
2.
8 
± 
0.
6 
(1.
6, 
4.0
)
2.
2 
± 
0.
4 
(1.
3, 
3.6
) *
†
0.
00
4
 
G
LS
Ra
 (1
/se
c)
2.
7 
± 
0.
6 
(0.
9, 
3.3
)
2.
6 
± 
0.
5 
(0.
9, 
3.6
)
2.
6 
± 
0.
8 
(0.
8, 
3.3
)
0.
67
Va
lu
es
 a
re
 m
ea
n 
± 
SD
. R
an
ge
 p
ro
v
id
ed
 in
 p
ar
en
th
es
es
.
Le
an
, i
nf
an
ts
 b
or
n 
to
 w
o
m
en
 w
ith
ou
t o
be
sit
y 
or
 d
ia
be
te
s; 
O
be
se
, i
nf
an
ts
 b
or
n 
to
 w
o
m
en
 w
ith
 o
be
sit
y 
bu
t n
ot
 d
ia
be
te
s; 
O
be
se
 +
 D
M
: i
nf
an
ts
 b
or
n 
to
 w
o
m
en
 w
ith
 o
be
sit
y 
an
d 
di
ab
et
es
,
H
R
, h
ea
rt 
ra
te
; b
pm
, b
ea
ts 
pe
r m
in
ut
e,
 L
V,
 
le
ft 
ve
n
tr
ic
le
; L
V
M
, l
ef
t v
en
tr
ic
ul
ar
 m
as
s m
ea
su
re
d 
by
 M
-m
od
e 
ec
ho
ca
rd
io
gr
ap
hy
; L
V
M
I, 
le
ft 
ve
n
tr
ic
ul
ar
 m
as
s i
nd
ex
;
EF
,
 
eje
cti
on
 fr
act
ion
; S
F, 
sh
or
te
ni
ng
 fr
ac
tio
n;
 R
W
T,
 
re
la
tiv
e 
w
al
l t
hi
ck
ne
ss
; S
W
T,
 
se
pt
al
 w
al
l t
hi
ck
ne
ss
G
LS
, g
lo
ba
l l
on
gi
tu
di
na
l s
tra
in
; G
LS
Rs
, g
lo
ba
l l
on
gi
tu
di
na
l s
ys
to
lic
 st
ra
in
 ra
te
; G
LS
Re
, e
ar
ly
 g
lo
ba
l l
on
gi
tu
di
na
l d
ia
sto
lic
 st
ra
in
 ra
te
;; 
G
LS
Ra
, l
at
e 
gl
ob
al
 lo
ng
itu
di
na
l d
ia
sto
lic
 st
ra
in
 ra
te
*
p<
0.
05
 O
B 
+ 
D
M
 v
s. 
Le
an
*
*
p<
0.
05
 O
B 
vs
. L
ea
n
† p
<0
.0
5 
O
B+
D
M
 v
s. 
O
B
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